journal
MENU ▼
Read by QxMD icon Read
search

Drugs in Context

journal
https://read.qxmd.com/read/30873213/the-therapeutic-role-of-minocycline-in-parkinson-s-disease
#1
REVIEW
Seyda Cankaya, Baris Cankaya, Ulkan Kilic, Ertugrul Kilic, Burak Yulug
Minocycline, a semisynthetic tetracycline-derived antibiotic, has been shown to exert anti-apoptotic, anti-inflammatory, and antioxidant effects. Furthermore, there is rapidly growing evidence suggesting that minocycline may have some neuroprotective activity in various experimental models such as cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, Parkinson's disease (PD), Huntington's disease, and multiple sclerosis. In this perspective review, we summarize the preclinical and clinical findings suggesting the neuroprotective role of minocycline in PD...
2019: Drugs in Context
https://read.qxmd.com/read/30853998/efficacy-of-ruxolitinib-retreatment-in-a-patient-with-high-risk-myelofibrosis-using-the-international-prognostic-scoring-system
#2
Vincenzo Accurso, Marco Santoro, Salvatrice Mancuso, Marisante Napolitano, Florinda Di Piazza, Antonio Russo, Sergio Mario Siragusa
No abstract text is available yet for this article.
2019: Drugs in Context
https://read.qxmd.com/read/30828352/the-efficacy-of-certolizumab-pegol-in-rheumatoid-arthritis-assessed-by-gray-scale-and-power-doppler-ultrasonography-case-reports
#3
José Alexandre Mendonça, Guilherme B Damian
No abstract text is available yet for this article.
2019: Drugs in Context
https://read.qxmd.com/read/30815024/chimeric-antigen-receptor-t-cell-therapy-for-b-cell-non-hodgkin-lymphoma-opportunities-and-challenges
#4
REVIEW
Shinichi Makita, Katsuaki Imaizumi, Saiko Kurosawa, Kensei Tobinai
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective therapy to overcome chemorefractory B-cell NHL. Based on the promising results obtained from pivotal trials, the US Food and Drug Administration and European Medicines Agency approved anti-CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma...
2019: Drugs in Context
https://read.qxmd.com/read/30815023/oral-oncolytic-and-antiretroviral-therapy-administration-dose-adjustments-drug-interactions-and-other-considerations-for-clinical-use
#5
REVIEW
Melissa E Badowski, Bradley Burton, Kristy M Shaeer, John Dicristofano
The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for HIV and cancer patients. To address this, current literature and guidelines suggest the continuation of antiretroviral therapy (ART) with oral oncolytic agents to prevent adverse complications associated with HIV disease progression. However, such an approach has the potential for drug-drug interactions and adverse events for patients on such therapy. Further, recommendations on how to adjust these medications, when used concomitantly, are limited...
2019: Drugs in Context
https://read.qxmd.com/read/30774692/medication-adherence-and-treatment-resistant-hypertension-a-review
#6
REVIEW
Mohammed Awais Hameed, Indranil Dasgupta
Nonadherence is a common reason for treatment failure and treatment resistance. No matter how it is defined, it is a major issue in the management of chronic illnesses. There are numerous methods to assess adherence, each with its own strengths and weaknesses; however, no single method is considered the best. Nonadherence is common in patients with hypertension, and it is present in a large proportion of patients with uncontrolled blood pressure taking three or more antihypertensive agents. Availability of procedure-based treatment options for these patients has shed further light on this important issue with development of new methods to assess adherence...
2019: Drugs in Context
https://read.qxmd.com/read/30719052/influence-of-the-duration-of-hospital-length-of-stay-on-frequency-of-prophylaxis-and-risk-for-venous-thromboembolism-among-patients-hospitalized-for-acute-medical-illnesses-in-the-usa
#7
Alpesh Amin, W Richey Neuman, Melissa Lingohr-Smith, Brandy Menges, Jay Lin
Background: We evaluated whether the duration of hospital stay influences venous thromboembolism (VTE) prophylaxis patterns and VTE risk during hospitalization and post-discharge among patients hospitalized for acute illnesses in the USA. Methods: Patients hospitalized for acute illnesses were identified from the US MarketScan Commercial and Medicare databases (January 1, 2012-June 30, 2015). Patients were stratified by index hospital length of stay (LOS), with study groups with 1-3 day, 4-6 day, and ≥7 day LOSs...
2019: Drugs in Context
https://read.qxmd.com/read/30636965/menopause-hormone-therapy-latest-developments-and-clinical-practice
#8
REVIEW
Tomas Fait
Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors.
2019: Drugs in Context
https://read.qxmd.com/read/30627206/anti-angiogenesis-therapy-synthetic-lethality-and-checkpoint-inhibition-in-ovarian-cancer-state-of-the-science-and-novel-combinations
#9
REVIEW
Marisa C Liu, Krishnansu S Tewari
Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.
2018: Drugs in Context
https://read.qxmd.com/read/30622585/penile-warts-an-update-on-their-evaluation-and-management
#10
REVIEW
Alexander Kc Leung, Benjamin Barankin, Kin Fon Leong, Kam Lun Hon
Background: Penile warts are the most common sexually transmitted disease in males. Clinicians should be familiar with the proper evaluation and management of this common condition. Objective: To provide an update on the current understanding, evaluation, and management of penile warts. Methods: A PubMed search was completed in Clinical Queries using the key terms 'penile warts' and 'genital warts'. The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews...
2018: Drugs in Context
https://read.qxmd.com/read/30574170/treatment-of-acute-bacterial-skin-and-skin-structure-infection-with-single-dose-dalbavancin-in-persons-who-inject-drugs
#11
Pedro Luis Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S McGregor, Sailaja Puttagunta, Michael W Dunne
Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, complicate the medical care of the PWID population, adversely affecting patient outcomes. Methods: We assessed demographics and outcomes for the PWID population in a double-blind trial of 698 patients randomized to dalbavancin 1500 mg as a single intravenous (IV) infusion or as a 2-dose regimen (1000 mg IV on day 1; 500 mg IV on day 8) for ABSSSI...
2018: Drugs in Context
https://read.qxmd.com/read/30534175/severe-refractory-asthma-current-treatment-options-and-ongoing-research
#12
REVIEW
Francesco Menzella, Francesca Bertolini, Mirella Biava, Carla Galeone, Chiara Scelfo, Marco Caminati
Patients with severe asthma have a greater risk of asthma-related symptoms, morbidities, and exacerbations. Moreover, healthcare costs of patients with severe refractory asthma are at least 80% higher than those with stable asthma, mainly because of a higher use of healthcare resources and chronic side effects of oral corticosteroids (OCS). The advent of new promising biologicals provides a unique therapeutic option that could achieve asthma control without OCS. However, the increasing number of available molecules poses a new challenge: the identification and selection of the most appropriate treatment...
2018: Drugs in Context
https://read.qxmd.com/read/30532792/dismissing-the-fallacies-of-childhood-eczema-management-case-scenarios-and-an-overview-of-best-practices
#13
REVIEW
Kam Lun Hon, Kin Fon Leong, Theresa Nh Leung, Alexander Kc Leung
Background: Eczema or atopic dermatitis (AD) is a common relapsing childhood dermatologic illness. Treatment of AD is primarily topical with emollients and corticosteroid/calcineurin inhibitor, which is efficacious for the majority of patients. However, AD is often complicated and difficult to manage in many Asian cities. Effective therapy is impeded by fallacies in the following aspects: (1) mistrust and unrealistic expectations about Western medicine, (2) skin care and allergy treatment, (3) ambiguity about optimal bathing and moisturizing, (4) hesitation and phobias about the usage of adequate topical corticosteroid and immunomodulatory therapies, (5) food and aeroallergen avoidance and dietary supplementation, and (6) complementary and alternative therapies...
2018: Drugs in Context
https://read.qxmd.com/read/30515229/impact-of-lipid-lowering-therapy-on-glycemic-control-and-the-risk-for-new-onset-diabetes-mellitus
#14
REVIEW
Constantine E Kosmas, Delia Silverio, Andreas Sourlas, Frank Garcia, Peter D Montan, Eliscer Guzman
Lipid-lowering therapy is used very commonly nowadays not only for the optimization of the lipid profile but also to reduce cardiovascular risk. However, some studies have linked the use of certain lipid-lowering agents with an increased risk for impaired glycemic control and new-onset diabetes mellitus, a condition well established as an important risk factor for cardiovascular disease. On the other hand, some other lipid-lowering agents have been shown to have a beneficial effect on glucose metabolism. Profound knowledge of these differences would enable the clinician to choose the right lipid-lowering medication for each individual patient, so that the benefits would outweigh the risk of side effects...
2018: Drugs in Context
https://read.qxmd.com/read/30483351/impact-of-adalimumab-on-clinical-outcomes-healthcare-resource-utilization-and-sick-leave-in-patients-with-ankylosing-spondylitis-an-observational-study-from-five-central-and-eastern-european-countries
#15
Daniela Opris-Belinski, Shandor F Erdes, Simeon Grazio, Ladislav Šenolt, Maja Hojnik, Orsolya Nagy, Diana Marina, Sándor Szántó
Background: Patients with ankylosing spondylitis (AS) are substantial users of healthcare resources due to chronic and potentially disabling disease. This study assessed the impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with AS in five Central and Eastern Europe (CEE) countries. Methods: This was an observational study in the routine clinical setting. Patients diagnosed with AS and starting treatment with originator adalimumab were followed for 12 months by assessing disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Ankylosing Spondylitis Disease Activity Score [ASDAS]) and physical function (Bath Ankylosing Spondylitis Functional Index [BASFI])...
2018: Drugs in Context
https://read.qxmd.com/read/30483350/the-metabolic-model-of-heart-failure-the-role-of-sodium-glucose-co-transporter-2-sglt-2-inhibition
#16
REVIEW
Muhammad Saad, Umut Gomceli, Pranav Ravi, Andrisael G Lacoste, Neil Shah, Timothy J Vittorio
Heart failure (HF) is one of the leading causes of hospital readmissions and health care expenditures. With a vast degree of advancements in the clinical approach and diagnosis, its management protocol is limited in terms of enhancing quality of life and prognosis. Type 2 diabetes mellitus (T2DM) is considered as one of the commonly associated comorbid conditions in the HF population. The understanding of the molecular and metabolic models of HF has led to the utilization of therapeutic goals of T2DM in improving HF-related complications...
2018: Drugs in Context
https://read.qxmd.com/read/30459819/repurposing-existing-drugs-for-cardiovascular-risk-management-a-focus-on-methotrexate
#17
REVIEW
Arduino A Mangoni, Sara Tommasi, Angelo Zinellu, Salvatore Sotgia, Ciriaco Carru, Matteo Piga, Gian Luca Erre
About 20% of patients with a history of atherosclerotic cardiovascular disease will experience further cardiovascular events despite maximal pharmacological treatment with cardioprotective drugs. This highlights the presence of residual cardiovascular risk in a significant proportion of patients and the need for novel, more effective therapies. These therapies should ideally target different pathophysiological pathways involved in the onset and the progression of atherosclerosis, particularly the inflammatory and immune pathways...
2018: Drugs in Context
https://read.qxmd.com/read/30416529/a-paradigm-shift-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hr-her2-advanced-breast-cancer-a-review-of-cdk-inhibitors
#18
REVIEW
Mariane Teodoro Fernandes, Jacob J Adashek, Carmelia Maria Noia Barreto, Ana Cláudia Barbin Spinosa, Barbara de Souza Gutierres, Gilberto Lopes, Auro Del Giglio, Pedro Nazareth Aguiar
In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2- advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment...
2018: Drugs in Context
https://read.qxmd.com/read/30416528/sublingual-allergen-immunotherapy-for-respiratory-allergy-a-systematic-review
#19
Carlos Blanco, Raphaelle Bazire, Laura Argiz, Jenaro Hernández-Peña
The objective of the systematic review is to provide complete and updated information on efficacy and safety of sublingual immunotherapy (SLIT) formulations for the treatment of allergic respiratory diseases (ARDs). The literature search was conducted on PubMed database, involving double-blind, randomized clinical trials published between January 1992 and 2018, written in English, and performed in humans. The number of articles finally selected for review was 112. Data from the majority of properly controlled clinical trials demonstrate that SLIT is effective not only with short-term use (first year) but also with long-term use (up to the third year of active therapy), for treating ARDs in children and adults...
2018: Drugs in Context
https://read.qxmd.com/read/30302115/the-biosimilars-journey-current-status-and-ongoing-challenges
#20
REVIEW
Igor Age Kos, Valderílio Feijó Azevedo, Daniel Egg Neto, Sérgio Cândido Kowalski
Biosimilar products are already approved and marketed in several countries. The Food and Drug Administration has approved ten different biosimilars, and the European Medicines Agency has approved 40. Even though this scenario has provided important experience with biosimilar products, there are still challenges and unanswered questions. Up to now, a good amount of knowledge has been gathered in order to support the importance of the totality of evidence and the construction of a biosimilarity exercise for regulatory approval...
2018: Drugs in Context
journal
journal
48111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"